The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma
Open accessAbstract
We conducted a phase 1/2 trial of high-dose 90Y-ibritumomab tiuxetan in combination with high-dose etoposide (VP-16) 40 to 60 mg/kg (day -4) and cyclophosphamide 100 mg/kg (day -2) followed by autologous stem cell transplantation (ASCT) in 31 patients with CD20+ non-Hodgkin lymphoma (NHL). Patients underwent dosimetry (day -21) with 5 mCi (185 MBq) 111In-ibritumomab tiuxetan following 250 mg/m2 rituximab, followed a week later by 90Y-ibritumomab tiuxetan to deliver a target dose of 1000 cGy to highest normal organ. Bone marrow biopsy was done on day -7 to estimate radiation dose and stem cells were reinfused when the radiation dose was estimated to be less than 5 cGy. The median 90Y-ibritumomab tiuxetan dose was 71.6 mCi (2649.2 MBq; range, 36.6-105 mCi; range, 1354.2-3885 MBq). Histology included follicular lymphoma (n = 12), diffuse large B-cell (n = 14), and mantle cell (n = 5). The median number of prior chemo-therapy treatments was 2. The treatment was well tolerated. The median times to reach an absolute neutrophil count greater than 500/μL and platelet count more than 20 000/μL were 10 days and 12 days, respectively. There were 2 deaths and 5 relapses. At a median follow-up of 22 months, the 2-year estimated overall survival and relapse-free survival rates are 92% and 78%, respectively. We conclude that high-dose 90Y-ibritumomab tiuxetan can be combined safely with high-dose etoposide and cyclophosphamide without an increase in transplant-related toxicity or delayed engraftment. (Blood. 2005;106:2896-2902)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support
Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D., Porter, B., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310213291702 · Cited by 644
Cited by
Radioimmunotherapy of human tumours
Larson, S. M., Carrasquillo, J. A., Cheung, N.-K. V., & Press, O. W. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3925 · Cited by 537
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Friedberg, J. W. (2011) · Hematology · doi:10.1182/asheducation-2011.1.498 · Cited by 497
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
Cheson, B. D., & Leonard, J. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708875 · Cited by 438
The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis
Jain, A., & Cheng, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.016 · Cited by 304
Metadata
- Authors
- Nademanee, A., Forman, S., Molina, A., Fung, H., Smith, D., Dagis, A., Kwok, C., Yamauchi, D., Anderson, A.-L., Falk, P., Krishnan, A., Kirschbaum, M., Kogut, N., Nakamura, R., O'Donnell, M., Parker, P., Popplewell, L., Pullarkat, V., Rodriguez, R., Sahebi, F., Smith, E., Snyder, D., Stein, A., Spielberger, R., Zain, J., White, C., & Raubitschek, A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2005-10-15
- Volume
- 106
- Issue
- 8
- Pages
- 2896-2902
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2116336389
- Cited by
- 201
- References
- 1
- FWCI
- 16.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. https://app.cochat.ai/papers/10.1182/blood-2005-03-1310
- The paper
- Nademanee, A., Forman, S., Molina, A., Fung, H., Smith, D., Dagis, A., Kwok, C., Yamauchi, D., Anderson, A.-L., Falk, P., Krishnan, A., Kirschbaum, M., Kogut, N., Nakamura, R., O'Donnell, M., Parker, P., Popplewell, L., Pullarkat, V., Rodriguez, R., . . . Raubitschek, A. (2005). A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood. https://doi.org/10.1182/blood-2005-03-1310
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.